DCR-PHXC

Phase 2Small molecule

DDicerna Pharmaceuticals, Inc., a Novo Nordisk company

DCR-PHXC is one of 10 small molecule programs targeting Primary Hyperoxaluria Type 1. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Hyperoxaluria Type 1Active, not recruiting

Primary HyperoxaluriaActive, not recruiting

Primary Hyperoxaluria Type 1Phase 2

Active, not recruiting

Primary HyperoxaluriaPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Primary Hyperoxaluria

#DrugCompanyPhaseTrials

Givlaari

Alnylam Pharmaceuticals

Cystadane

1 3

Diacomit

BBiocodex

Phase 2

1 4

DCR-PHXC

DDicerna Pharmaceuticals, Inc., a Novo Nordisk company

Phase 2

2 5

Oxalobacter Formigenes

OOxThera

Phase 2

2 6

ALLN-177

AAllena Pharmaceuticals

Phase 2

1 7

YOLT-203

RRenJi Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Active, not recruiting

Primary Hyperoxaluria

NCT04042402

Q1 2032

Phase 2Recruiting

Efficacy

NCT04580420

Clinical

Trials by Indication[1]

Primary Hyperoxaluria2 trials

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

Completed·DDicerna Pharmaceuticals, Inc., a Novo Nordisk company·Phase 1·NCT03392896·43 enrolled

Long Term Extension Study in Patients With Primary Hyperoxaluria

Active, not recruiting·DDicerna Pharmaceuticals, Inc., a Novo Nordisk company·Phase 3·NCT04042402·75 enrolled

Efficacy1 trial

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Recruiting·DDicerna Pharmaceuticals, Inc., a Novo Nordisk company·Phase 2·NCT04580420·28 enrolled

Primary Hyperoxaluria Type 11 trial

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03847909·35 enrolled

Unspecified1 trial

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

Completed·DDicerna Pharmaceuticals, Inc., a Novo Nordisk company·Phase 1·NCT04555486·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DCR-PHXC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DCR-PHXC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DCR-PHXC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dicerna Pharmaceuticals, Inc., a Novo Nordisk company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDicerna Pharmaceuticals, Inc., a Novo Nordisk company

DCR-PHXC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q1 2032

Trials by Indication[1]

Primary Hyperoxaluria2 trials

Efficacy1 trial

Primary Hyperoxaluria Type 11 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News